Le melanome metastatique: un vent d'espoir porte par l'ipilimumab et le vemurafenib.

Antibodies, Monoclonal/adverse effects/pharmacology/therapeutic use; Antineoplastic Agents/adverse effects/pharmacology/therapeutic use; Humans; Indoles/adverse effects/pharmacology/therapeutic use; Melanoma/drug therapy/pathology; Neoplasm Metastasis; Neoplasm Staging; Skin Neoplasms/drug therapy/pathology; Sulfonamides/adverse effects/pharmacology/therapeutic use; Survival Rate; Translational Medical Research

Abstract :

[en] Treating a patient with cutaneous malignant melanoma relies on the recognition of a clever stratification of the distinct stages of the disease. The histoprognostic criteria were recently revisited. In addition, translational research fueled the development of new treatments with at last increased efficacy in the metastatic stage. Such therapeutic advance improves the median overall survival for a few months. Some combined treatments could possibly boost the beneficial effects.

Disciplines :

Dermatology

Author, co-author :

Franchimont, Claudine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

Le melanome metastatique: un vent d'espoir porte par l'ipilimumab et le vemurafenib.

Alternative titles :

[en] Metastatic melanoma: some hope from ipilimumab and vemurafenib

Publication date :

2012

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

64-8

Peer reviewed :

Peer reviewed

Available on ORBi :

since 10 February 2013

Statistics

Number of views

150 (8 by ULiège)

Number of downloads

619 (11 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Balch CM, Gershenwald JE, Song SJ, et al. - Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol, 2009, 27, 6199-6206.
Schmoeckel C, Braun-Falco O. - The prognostic index in malignant melanoma. Arch Dermatol, 1978, 1141, 871-873.
Piérard-Franchimont C, Piérard GE. - Did we make any progress in the control of malignant melanoma since 1955? Cancer J, 1989, 3, 472-475. (Pubitemid 20031659)
Piérard GE, Piérard-Franchimont C, Henry C, Lapière M. - The proliferative activity of cells of malignant melanomas. Am J Dermatopathol, 1984, 6, S317-S324.
Quatresooz P, Arrese JE, Piérard-Franchimont C, et al.- Immunohistochemical aid at risk stratification of melanocytic neoplasms. Int J Oncol, 2004, 24, 211-216.
Quatresooz P, Piérard GE, Piérard-Franchimont C, et al. - Molecular pathways supporting the proliferation staging of malignant melanoma. Int J Mol Med, 2009, 24, 295-301.
Quatresooz P, Piérard-Franchimont C, Paquet P, Piérard GE. - Angiogenic fast-growing melanomas and their micrometastases. Eur J Dermatol, 2010, 20, 302-307.
Quatresooz P, Piérard GE. - Malignant melanoma : from cell kinetics to micrometastases. Am J Clin Dermatol, 2011, 12, 77-86.
Piérard GE. - Spotlight on cell proliferation in malignant melanoma : relationship with neoplastic progression. Int Scholarly Res Network, 2011, 2011, 828146.
Shibata K, Inagaki M, Ajiro K. - Mitosis-specific histone H3 phosphorylation in vitro in nucleosome structures. Eur J Biochem, 1990, 192, 87-93. (Pubitemid 20277510)
Nading MA, Balch CM, Sober AJ. - Implication of the 2009 American Joint Committee on Cancer Melanoma Stagint and Classification on dermatologists and their patients. Semin Cutan Med Surg, 2010, 29, 142-147.
Claessens N, Piérard GE, Piérard-Franchimont C, et al. - Immunohistochemical detection of incipient melanoma micrometastases. Relationship with sentinel lymph node involvement. Melanoma Res, 2005, 15, 107-110. (Pubitemid 40637988)
Balch CM, Gershenwald JE, Soong SJ, et al. - Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma : comparison of nodal micrometastases versus macrometastases. J Clin Oncol, 2010, 28, 2452-2459.
Heidorn SJ, Milagre C, Whittaker S, et al. - Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 2010, 140, 209-221.
Long GV, Menzies AM, Nagrial AM, et al. - Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol, 2011, 29, 1239-1246.
Reginster MA, Piérard-Franchimont C, Piérard GE, et al. - Molecular dermatopathology in malignant melanoma. Dermatol Res Pract, 2012, 2012, 684032.
Chapman PB, Hauschild A, Robert C, et al. - BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 364, 2507-2516.
Nazarian R, Shi H, Wang Q, et al. - Melanomas acquire resistance to BRAF (V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010, 468, 973-977.
Hodi FS, O'Day SJ, McDermott DF, et al. - Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010, 363, 711-723.
Piérard GE, Aubin F, Humbert P. - Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma ? Dermatol Res Pract, 2012, 2012, 182157.
Robert C, Thomas L, Bondarenko I, et al. - Ipilimumab plus dacarbazine for previsouly untreated metastatic melanoma. N Engl J Med, 2011, 364, 2517-2526.
Minkis K, Garden BC, Wu S, Lacouture ME. - Risk of skin rash associated with ipilimumab : a systematic review of litterature and meta-analysis. Melanoma Res, sous presse.